Skip to main content
. Author manuscript; available in PMC: 2014 Apr 14.
Published in final edited form as: Ann Surg. 2014 Apr;259(4):793–799. doi: 10.1097/SLA.0b013e3182a6f552

FIGURE 3.

FIGURE 3

The effects of sunitinib (SUN) in luminal breast cancer are mediated by the RET receptor. (A), Western blot demonstrating RET expression in the luminal breast cancer cell line BT-474 and confirming effectiveness of RET siRNA to eliminate RET expression. (B), Treatment with sunitinib reduces cell growth in BT-474 with additive results when combined with tamoxifen (TAM) treatment. (C), Treatment with sunitinib or vandetanib reduced viability in MCF-7 and BT-474. Knockdown of RET expression by siRNA eliminated the antiproliferative effects of treatment of both sunitinib and vandetanib in both cell lines. For both cell lines, data were normalized to NT transfection without drug treatment.